1st Quarter - Report
SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC
Client
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
End Stage Renal Disease (ESRD) bundling and non-injectable oral equivalents; State Medicare waiver and Elaprase
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOFF MASUKAWA | — |
Health Issues HCR
H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, Health Care and Education Reconciliation Act Issues related to biosimilar approval pathway, healthcare reform, orphan drugs, end stage renal disease bundling and non-injectable oral equivalents; state Medicare waiver and Elaprase
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOFF MASUKAWA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.